Links
Organizations
Conferences
Info & Opinion
- Applied Clinical Trials
- Bio-IT World
- ClinPsych
- Clinical Trials Today
- Tom Lamb
- George Laszlo
- Pharma Voice
- Ed Silverman
- TJOLS
December 3, 2008
New Diabetes Endpoints?
NEJM Hits Post-Approval Trials
Is the FDA a new target of the New England Journal of Medicine? Maybe. Late last month, the journal has an article by the head of the Avandia advisory committee that casts a skeptical eye on observational trials.
- Home
- Tag
- rosen
Concerns about diabetes blockbuster Avandia have been addressed by the mass media, by FDA statements—and by the August 30, 2007, New England Journal of Medicine (NEJM). It’s not a surprise that the journal would have a negative view of the…
No articles available
